Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Kodiak's Zenkuda drug met key trial targets for diabetic retinopathy, boosting investor confidence.

flag Kodiak Sciences shares surged after its drug Zenkuda met primary endpoints in a late-stage diabetic retinopathy trial. flag The treatment showed significant improvement in disease severity and reduced sight-threatening complications, with a strong safety profile. flag The company plans to accelerate regulatory submissions, boosting investor confidence.

9 Articles